


PHARMACEUTICAL 2021



BIODELIVERY SCIENCES INTERNATIONAL INC Rank 43 of 409







PHARMACEUTICAL 2021



BIODELIVERY SCIENCES INTERNATIONAL INC Rank 43 of 409



The relative strengths and weaknesses of BIODELIVERY SCIENCES INTERNATIONAL INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of BIODELIVERY SCIENCES INTERNATIONAL INC compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 379% points. The greatest weakness of BIODELIVERY SCIENCES INTERNATIONAL INC is the variable Selling, General and Administrative Expense, reducing the Economic Capital Ratio by 62% points.

The company's Economic Capital Ratio, given in the ranking table, is 120%, being 475% points above the market average of -355%.

Input Variable	Value in 1000 USD
Assets, Current	182,385
Cost of Goods Sold	24,665
Intangible Assets	2,715
Liabilities, Current	52,995
Liabilities, Non-Current	213
Other Assets	54,794
Other Compr. Net Income	0
Other Expenses	252
Other Liabilities	78,452
Other Net Income	-7,016
Property and Equipment	0
Research and Development	0
Revenues	156,471
Selling, General and Administrative Expense	98,827

Output Variable	Value in 1000 USD
Assets	239,894
Liabilities	131,660
Expenses	123,744
Stockholders Equity	108,234
Net Income	25,711
Comprehensive Net Income	25,711
Economic Capital Ratio	120%